Company intelligence / Profile preview

Nosis Biosciences

Berkeley, California, United States

Ownership: Private
Development stage: Other

Overview

The lead fibrosis program was nominated as a development candidate in July 2025 and is in IND-enabling studies as of Q3 2025; no clinical data has been reported yet. The company has preclinical programs for other indications and key partnerships for additional discovery-stage assets.[2][11]

Therapeutic areas: CardiovascularOtherNeurologyImmunology
Modalities: Small interfering RNAAntisense oligonucleotideProtein-drug conjugateRadiopharmaceuticalRNA therapy
Industry: Biotech

Drug pipeline

6 assets

Nosis-Tcell-001

Preclinical

5 more assets in the full pipeline.

Request access →

Partnerships

Daiichi Sankyo (platform collaboration for cell-targeted RNA therapeutics development)[4][6][7]Johnson & Johnson (platform/drug discovery collaboration for cell-targeted RNA therapeutics)[6][8]

Beyond the preview

Go deeper on Nosis Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nosis Biosciences.

Explore the full profile